Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877909 | 0.79 | GRM5 (0.46) | GRM5NPC1MTORRAB9ACA12 | |
| SCHEMBL14617540 | 0.75 | SDHB (0.39) | GRM5NPC1MTORRAB9A | |
| SCHEMBL6885670 | 0.75 | RAB9A (0.50) | NPC1RAB9A | |
| SCHEMBL25128702 | 0.74 | EGLN1 (0.37) | — | |
| SCHEMBL17705931 | 0.74 | GRM5 (0.62) | GRM5NPC1RAB9AAPP | |
| Diphenylacetylene SCHEMBL27721387 | 0.73 | APP (0.60) | GRM5NPC1MTORRAB9AAPP | |
| SCHEMBL7567240 | 0.72 | CA12 (0.64) | NPC1MTORRAB9AAPPCA12 | |
| SCHEMBL16835367 | 0.72 | KDM4E (0.43) | NPC1 | |
| SCHEMBL30983335 | 0.72 | HDAC8 (0.35) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL1476274 | 0.70 | PTGDR2 (0.50) | GRM5NPC1MTORRAB9AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493856-B1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN LA ROCHE (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315498-B2 | Arlethynyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2558457-B1 | ARYLETHYNYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-03-09 | — | — | EP | disclosed |
| EP-2763969-B1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2763969-B1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2763969-A1 | ETHYNYL DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20140155602-A1 | Arlethynyl Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2558457-A1 | ARYLETHYNYL DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2493856-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. Hoffmann-La Roche AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | GRM5 1/4885NPC1 3414/4885MTOR 1649/4885 |
| US-20140155602-A1 | Arlethynyl Derivatives | GRM5, GRIK5, GRM1 | GRM5 1/4885NPC1 2791/4885MTOR 2347/4885 |
| US-20110251169-A1 | Arylethynyl derivatives | GRM5, GRM1, GRM3 | GRM5 1/4885NPC1 2422/4885MTOR 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.